BIOMAT Database Logo BIOMAT Database Logo

Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type I diabetes mellitus. 1981

F L Dunn, and A Pietri, and P Raskin

Plasma lipid and lipoprotein-cholesterol levels were measured in 10 insulin-dependent (Type I) diabetics taking their usual dose of conventionally administered insulin during 6 months of a continuous subcutaneous insulin infusion delivered with a small, portable, battery-powered pump. With this insulin delivery system we were able to provide near normal glucoregulation 24 hours a day for the entire study. This improved glucoregulation resulted in significant reductions in total plasma cholesterol and triglyceride, and very low density and low density lipoprotein-cholesterol levels within 2 to 4 weeks of treatment. These changes persisted for the entire 6 months of observation. High density lipoprotein-cholesterol levels rose significantly after 2 months of treatment and continued to increase during the 6-month study. These changes in plasma lipid and lipoprotein-cholesterol levels in response to treatment with continuous subcutaneous insulin infusion would favorably alter the predicted risk for the development of premature atherosclerosis in these patients.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F L Dunn, and A Pietri, and P Raskin
Plasma lipid fatty acids and platelet function during continuous subcutaneous insulin infusion in type I diabetes.
June 1987, Diabete & metabolisme,
F L Dunn, and A Pietri, and P Raskin
[Treatment of type I diabetes mellitus with continuous subcutaneous insulin infusion: indications and quality control].
January 1989, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
F L Dunn, and A Pietri, and P Raskin
[Continuous subcutaneous insulin infusion in pediatric patients with type 1 diabetes mellitus].
January 2006, Anales de pediatria (Barcelona, Spain : 2003),
F L Dunn, and A Pietri, and P Raskin
Continuous subcutaneous insulin infusion in patients with diabetes mellitus.
April 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
F L Dunn, and A Pietri, and P Raskin
Insulin-binding to erythrocytes in type I diabetes mellitus: effects of continuous subcutaneous infusion of insulin.
January 1984, Clinical and investigative medicine. Medecine clinique et experimentale,
F L Dunn, and A Pietri, and P Raskin
Continuous subcutaneous insulin infusion in neonatal diabetes mellitus.
December 2004, Pediatric diabetes,
F L Dunn, and A Pietri, and P Raskin
Continuous subcutaneous insulin infusion pump treatment in children with type 1 diabetes mellitus.
February 2004, Journal of pediatric endocrinology & metabolism : JPEM,
F L Dunn, and A Pietri, and P Raskin
[Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes mellitus].
June 2012, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
F L Dunn, and A Pietri, and P Raskin
Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion.
June 2003, Journal of thrombosis and haemostasis : JTH,
F L Dunn, and A Pietri, and P Raskin
[Treatment with continuous subcutaneous insulin infusion in pediatric patients with type 1 diabetes mellitus].
June 2006, Anales de pediatria (Barcelona, Spain : 2003),
Copied contents to your clipboard!